Physician profile
Michael Thomas
NPI 1023098506
$30,065.64
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $7,660 · 2021: $697 · 2022: $2,818 · 2023: $618 · 2024: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $24,518.49 | 2019-2024 | Korlym |
| Biomarin Pharmaceutical INC. | $2,457.00 | 2022 | |
| Radius Health, INC. | $364.58 | 2019-2024 | Tymlos |
| Abbvie INC. | $294.92 | 2019-2024 | Synthroid |
| Horizon Therapeutics Plc | $267.89 | 2019-2023 | Tepezza |
| Antares Pharma, INC. | $258.48 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Lilly USA, LLC | $200.78 | 2021-2024 | Retevmo, Jardiance, Zepbound |
| Amgen INC. | $186.27 | 2019-2024 | Tepezza, Evenity, Prolia |
| Ibsa Pharma INC. | $177.74 | 2020-2024 | Tirosint, Tirosint, Licart |
| Recordati_rare_diseases_inc. | $175.88 | 2020-2024 | Signifor Lar, Isturisa |
| Alexion Pharmaceuticals, INC. | $172.24 | 2019-2022 | |
| Novo Nordisk INC | $142.18 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $131.60 | 2022-2023 | Recorlev, Keveyis |
| Shire North American Group INC | $92.40 | 2019 | |
| Pfizer INC. | $80.46 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $68.84 | 2020 | |
| Chiesi USA, INC. | $60.01 | 2024 | Mycapssa |
| Chiasma, INC. | $59.99 | 2021 | |
| Amneal Pharmaceuticals LLC | $52.57 | 2022-2023 | Unithroid |
| Ascendis Pharma Endocrinology INC | $43.73 | 2023 | |
| Dermira, INC. | $36.97 | 2020 | |
| Medtronic, INC. | $33.06 | 2023 | Intellis Adaptivestim |
| Clarus Therapeutics INC. | $32.85 | 2021 | |
| Tolmar, INC. | $29.14 | 2023 | |
| Kyowa Kirin, INC. | $24.85 | 2024 | Crysvita |
| Aytu Biopharma, INC. | $19.42 | 2019 | |
| Strongbridge US INC. | $18.21 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2020 | |
| Vistapharm, INC. | $14.29 | 2021 | |
| Acella Pharmaceuticals, LLC | $13.06 | 2021 | |
| Janssen Scientific Affairs, LLC | $10.82 | 2019 | |
| Optos, INC. | $10.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.